T-Therapeutics is on a mission to unlock the power of T cells to treat chronic and infectious diseases.
Founded in 2022, the company is based on technology from Professor Allan Bradley’s laboratory in Cambridge University’s Department of Medicine.
Professor Allan Bradley has previously founded several companies including Kymab, a company developing fully human monoclonal antibodies with a focus on immune-mediated diseases and immuno-oncology therapeutics, which was acquired by Sanofi in 2021 for $1.45 billion.
T-Therapeutics has already raised investment from “a blue-chip syndicate of investors” to support its drug discovery efforts and prepare candidates for clinical development. It is currently building facilities, recruiting staff, and establishing its research operations.
Subscribe for alerts on new companies featured on Startups.Bio
The biotechnology sector is advancing rapidly, fueled by significant venture capital investments that are enabling companies to achieve major breakthroughs. To stay informed about the latest funding activities and discover …
Founded in 2024, Analona Therapeutics is a biotech company located in Denmark focused on developing innovative antibody-based therapies for pancreatic cancer. The company is built on cutting-edge research from the …
U-Ploid Biotechnologies aims to revolutionize IVF for Age-Related Infertility. Millions of women around the world face the emotional and financial toll of age-related infertility. As more individuals choose to start …
BioTryp Therapeutics is University of Cambridge spin-out biotechnology company that focuses on the development of small molecules to inhibit biofilm formation, which causes 80% of chronic and recurrent infections. BioTryp's …